Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel

E-mail:
abel@urology.wisc.edu

Phone:
(608) 262-2691

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Assistant Professor
Department of Urology

Education

  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

Funding/Grants
  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Haddad AQ, Wood CG, Abel EJ, Krabbe LM, Darwish OM, Thompson RH, Heckman JE, Merril MM, Gayed BA, Sagalowsky AI, Boorjian SA, Margulis V, Leibovich BC. Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with IVC Thrombus Extending Above the Hepatic Veins: A Contemporary Multi-Center Cohort. J. Urol. 2014 Apr 2.
    [PubMed ID: 24704115]
    More Information
  • Potretzke A, Hillman L, Wong K, Shi F, Brower R, Mai S, Cetnar JP, Abel EJ, Downs TM. NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder. Urol. Oncol. 2014 Mar 12.
    [PubMed ID: 24629498]
    More Information
  • Abel EJ, Thompson RH, Margulis V, Heckman JE, Merril MM, Darwish OM, Krabbe LM, Boorjian SA, Leibovich BC, Wood CG. Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. Eur. Urol. 2013 Nov 7.
    [PubMed ID: 24262104]
    More Information
  • Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol 2013 Nov-Dec; 39(6):817-22.
    [PubMed ID: 24456786]
    More Information
  • Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in non-metastatic RCC patients with tumor thrombus. BJU Int. 2013 Oct 15.
    [PubMed ID: 24128265]
    More Information
  • Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 2013 Nov 15; 119(22):3992-4002.
    [PubMed ID: 24006289]
    More Information
  • Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. J. Urol. 2013 Aug; 190(2):452-7.
    [PubMed ID: 23434945]
    More Information
  • Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur. Urol. 2013 May; 63(5):947-52.
    [PubMed ID: 23273681]
    More Information
  • Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Kohler TR, Kougias P, Jean-Claude JM, Cikrit DF, Swanson KM, OVER Veterans Affairs Cooperative Study Group . Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N. Engl. J. Med. 2012 Nov 22; 367(21):1988-97.
    [PubMed ID: 23171095]
    More Information
  • Patel SR, Abel EJ, Hedican SP, Nakada SY. Ablation of small renal masses: practice patterns at academic institutions in the United States. J. Endourol. 2013 Feb; 27(2):158-61.
    [PubMed ID: 22974005]
    More Information


webmaster@surgery.wisc.edu Copyright © 2014 The Board of Regents of the University of Wisconsin System